ReviewSeminars in interventional radiology2013
Chemoembolization of hepatocellular carcinoma.
Review in Seminars in interventional radiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 3 syntheses or guidelines pooled it, 223 citations in OpenAlex.
- The use of machine learning in transarterial chemoembolisation/transarterial embolisation for patients with intermediate-stage hepatocellular carcinoma: a systematic review.La Radiologia medica · 2025Pooled it
- Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.The Cochrane database of systematic reviews · 2017Pooled it
- Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.World journal of gastroenterology · 2014Pooled it
- A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization.European radiology · 2015Trial
- Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory.Cell reports. Medicine · 2026Article
- Safety and Treatment Efficacy of Systemic, Locoregional, and Nanoparticle Encapsulated Anthracycline Chemotherapy: Insights Into Cardiotoxicity.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Retrospective Analysis of the Clinical Efficacy, Safety, and Influencing Factors of Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatic Malignancies.Clinical Medicine Insights. Oncology · 2026Article
- Stereotactic body radiation therapy in patients with unresectable hepatocellular carcinoma and portal vein tumor thrombosis.World journal of hepatology · 2025Article
- Unveiling the Cytotoxicity Potential of Nanoemulsion ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma: survival outcomes and prognostic factors from a systematic review and meta-analysis.Hepatobiliary surgery and nutrition · 2025Article
- Article
- Article
- Article
- Personalized peripheral vascular interventional embolization for tumor: tailoring treatment to improve outcomes.Frontiers in medicine · 2025Review
- Lower MMP12 expression is likely to contribute to better effect of postoperative adjuvant transarterial chemoembolization via reducing MEK/ERK signaling activity in patients with hepatocellular carcinoma.American journal of cancer research · 2025Article
- Application of Nanotechnology in TACE Treatment of Liver Cancer.International journal of nanomedicine · 2025Review
- Biodegradable Microspheres for Transarterial Chemoembolization in Malignant Liver Disease.Medicina (Kaunas, Lithuania) · 2024Review
- Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma.Seminars in interventional radiology · 2024Review
- Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study.Anti-cancer agents in medicinal chemistry · 2024Article
- Analysis of the Efficacy and Safety of Palonosetron Hydrochloride in Preventing Nausea And Vomiting After TACE: A Retrospective Analysis.Current radiopharmaceuticals · 2024Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) and relatively preserved liver function. In a meta-analysis of randomized controlled trials comparing conventional TACE regimens-including the administration of an anticancer-in-oil emulsion followed by embolic agents-versus best supportive care, TACE was shown to improve median survival from 16 to 20 months. Various strategies to improve outcomes for this patient group have become the subject of much ongoing clinical research. The introduction of an embolic drug-eluting bead (DEB) has been shown to substantially improve the pharmacokinetic profile of TACE, providing levels of consistency and repeatability not available with conventional regimens while concomitantly significantly diminishing systemic drug exposure. In randomized trials, DEB-TACE significantly reduced liver toxicity and drug-related adverse events compared with conventional TACE. In this article, technique, indications and contraindications, and clinical outcomes of conventional and DEB-TACE in the management of HCC are reviewed. In addition, scientific background and early clinical experience with the use of combination regimens including TACE and systemically active molecular-targeted agents with antiangiogenic properties are discussed. The combination of DEB-TACE and antiangiogenic therapy represents a potentially powerful approach that is currently undergoing clinical investigation in a phase 3 setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.